- Trials with a EudraCT protocol (295)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
295 result(s) found for: Cell culture.
Displaying page 1 of 15.
EudraCT Number: 2011-005929-49 | Sponsor Protocol Number: VX11-787-101 | Start Date*: 2012-02-20 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus | |||||||||||||
Medical condition: Influenza A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001534-13 | Sponsor Protocol Number: V58P12 | Start Date*: 2007-11-08 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | ||
Full Title: A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cel... | ||
Medical condition: Healthy pediatric population from 3-17 years | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Completed) LT (Completed) FI (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004854-97 | Sponsor Protocol Number: A8851019 | Start Date*: 2008-01-15 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE... | |||||||||||||
Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001699-43 | Sponsor Protocol Number: BPR-CS-009 | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd | |||||||||||||
Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ... | |||||||||||||
Medical condition: Complicated staphylococcus aureus bacteremia (cSAB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004804-38 | Sponsor Protocol Number: 073-202 | Start Date*: 2011-12-13 | |||||||||||
Sponsor Name:ViroDefense Inc | |||||||||||||
Full Title: A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult V... | |||||||||||||
Medical condition: Poliomyelitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017939-18 | Sponsor Protocol Number: 08/0316 | Start Date*: 2010-12-15 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated w... | |||||||||||||
Medical condition: Chronic urinary tract infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002690-35 | Sponsor Protocol Number: OEV123 | Start Date*: 2017-05-08 | ||||||||||||||||
Sponsor Name:Scandinavian Biopharma AB | ||||||||||||||||||
Full Title: A randomized, placebo-controlled phase IIb (OEV 123) study to evaluate safety, immunogenicity, diagnostic methodology, and estimate vaccine efficacy of an oral enterotoxigenic Escherichia coli (ET... | ||||||||||||||||||
Medical condition: Healthy voluteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC]) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002883-15 | Sponsor Protocol Number: V130_12 | Start Date*: 2017-07-19 | |||||||||||
Sponsor Name:Seqirus UK Limited | |||||||||||||
Full Title: A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine C... | |||||||||||||
Medical condition: Profylaxis for Influenza virus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) EE (Completed) ES (Completed) FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002192-23 | Sponsor Protocol Number: GS-US-404-1808 | Start Date*: 2016-06-03 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects with Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001223-13 | Sponsor Protocol Number: V58_31 | Start Date*: 2014-12-03 |
Sponsor Name:Novartis Vaccines and Diagnostics | ||
Full Title: A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Ch... | ||
Medical condition: Prophylaxis: Influenza | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-003772-31 | Sponsor Protocol Number: IT001-302 | Start Date*: 2018-12-07 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe... | ||
Medical condition: Complicated urinary tract infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) EE (Ongoing) CZ (Completed) BG (Completed) SK (Completed) HR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004261-10 | Sponsor Protocol Number: AR-105-002 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Aridis Pharmaceuticals, Inc. | |||||||||||||
Full Title: Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia | |||||||||||||
Medical condition: Pseudomonas aeruginosa pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Completed) HU (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001857-29 | Sponsor Protocol Number: V130_14 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Seqirus UK Limited | |||||||||||||
Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to... | |||||||||||||
Medical condition: Prophylaxis of influenza virus infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003369-20 | Sponsor Protocol Number: CT-P59_3.2 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R... | |||||||||||||
Medical condition: SARS CoV 2 infection in outpatients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000468-27 | Sponsor Protocol Number: BVX-010 | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:BiondVax Pharmaceuticals Ltd. | |||||||||||||
Full Title: A pivotal, multicentre, randomized, modified double-blind, placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine administered intramuscularly tw... | |||||||||||||
Medical condition: Flu vaccination | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) LV (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000850-36 | Sponsor Protocol Number: 201600136 | Start Date*: 2017-05-01 |
Sponsor Name:Archivel Farma S.L. | ||
Full Title: Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculos... | ||
Medical condition: The medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and Isoniazid | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003665-10 | Sponsor Protocol Number: RBH2017/001 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust | |||||||||||||
Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors | |||||||||||||
Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003446-45 | Sponsor Protocol Number: TBTCS31/A5349 | Start Date*: 2016-02-25 |
Sponsor Name:Unidad de investigación en Tuberculosis de Barcelona | ||
Full Title: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial | ||
Medical condition: Pulmonary tuberculosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011895-31 | Sponsor Protocol Number: CLIN903 LCM201 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:STEBA BIOTECH | |||||||||||||
Full Title: EVALUATION OF THE SAFETY AND EFFICACY OF WST11 MEDIATED VASCULAR TARGETED PHOTODYNAMIC THERAPY ON OBSTRUCTING ENDOBRONCHIAL NON-SMALL CELL LUNG CANCER | |||||||||||||
Medical condition: Obstructive endobronchial non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003301-22 | Sponsor Protocol Number: AC-R6 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:Archivel Farma S.L. | |||||||||||||
Full Title: A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTI® immunotherapy with the standard treatment in patients with TB (CONSTAN) | |||||||||||||
Medical condition: Pulmonary Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
